In response to prescription drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing the federal government to negotiate the price of prescription drugs for Medicare and private payers. This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal government the authority to negotiate drug prices in Medicare, describes the negotiation provisions in key legislation (H.R. 3), ...| KFF
Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the pike for HR?| HR Executive
New study by Alex Olssen & Mark Pauly finds that many Medicare beneficiaries with high drug spending won’t reach Medicare’s new $2,000 out-of-pocket drug cap.| Penn LDI
On average, the new Medicare negotiated drug prices are 2.8 times the average of drug prices in 11 OECD countries of similar size and wealth.| Peterson-KFF Health System Tracker
This chart collection explores how health spending is expected to grow in coming years. In 2024, per capita health spending growth is estimated to have slowed to 4.5%.| Peterson-KFF Health System Tracker
This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.| KFF
The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.| KFF